New painkiller, with fewer side-effects, up for FDA approval

NewsGuard 100/100 Score

The drug, Moxduo, allows patients to take lower doses of other painkillers. Elsewhere, a Food and Drug Administration official talks about another painkiller, Zohydro.

NPR: Powerful Narcotic Painkiller Up For FDA Approval
The Food and Drug Administration is trying to decide whether to approve a powerful new prescription painkiller that's designed to relieve severe pain quickly, and with fewer side effects than other opioids. While some pain experts say the medicine could provide a valuable alternative for some patients in intense pain, the drug (called Moxduo) is also prompting concern that it could exacerbate the epidemic of abuse of prescription painkillers and overdoses. An FDA advisory committee is holding a daylong hearing Tuesday to decide whether to recommend that the agency approve the drug (Stein, 4/22).

CQ Healthbeat: FDA Official Urges Reassessment Of Painkiller Use
While defending the approval of the controversial painkiller Zohydro, the top U.S. drug regulator is calling for a reversal of the trends that have triggered excess use of narcotics in the United States and unleashed an epidemic of prescription drug abuse (Young, 4/22).


http://www.kaiserhealthnews.orgThis article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.

 

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Can you spot the difference? Study explores the appeal of AI-generated vs. real food images